Benjamin L. Judson, MD

Associate Professor of Surgery (Otolaryngology); Associate Residency Program Director, Otolaryngology; Medical Director, Ambulatory Clinics, Smilow Cancer Hospital at Yale-New Haven

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Adolescent; Child; Geriatric
Referrals: From patients or physicians

Patient Care Organizations

Surgery: Otolaryngology Surgery: Head & Neck Cancer Surgery Program

Yale Cancer Center: Head & Neck Cancers Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Otolaryngology AB of Otolaryngology (2008)

Clinical Trials

Conditions Study Title
Larynx, Lip, Oral Cavity and Pharynx A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Soft Tissue Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer
Larynx, Lip, Oral Cavity and Pharynx A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
Larynx, Lip, Oral Cavity and Pharynx Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Lip, Oral Cavity and Pharynx A Two-arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)
Larynx, Lip, Oral Cavity and Pharynx, Ill-Defined Sites A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Lip, Oral Cavity and Pharynx Window Trial 5-aza in HNSCC, T-tare

Edit this profile